Investor Summary

At O’VISTA, we’ve transformed cutting-edge neuroscience into a real-world solution for early Alzheimer’s risk assessment. Grounded in a rigorous systematic review and meta-analysis of over 145 studies (publicly archived on Zenodo and under peer review), our platform leverages timing-resolved eye-movement biomarkers—particularly antisaccade latency and error rate—to identify cognitive decline years before clinical symptoms appear. Our model delivers balanced sensitivity and specificity of ~73% (AUC ≈ 0.81), translating complex research into actionable, clinician-friendly decision support.

Unlike costly MRI or invasive CSF tests, O’VISTA offers a non-invasive, low-cost, browser-compatible solution—enhanced by our proprietary hardware for research-grade accuracy in everyday settings.

To accelerate global adoption, we are prioritizing a strategic launch in the Gulf and broader Middle East region. Regulatory pathways here are streamlined, healthcare innovation incentives are strong, and demand for scalable cognitive health tools is growing rapidly—making it an ideal testbed for real-world validation and early revenue generation.

Success in this region will de-risk our pathway to Europe, Canada, the U.S., and Australia, where Alzheimer’s affects over 55 million people globally (projected to reach 139 million by 2050). Our modular, GDPR/HIPAA-ready architecture ensures seamless compliance with stringent Western regulatory frameworks—positioning O’VISTA not just as a diagnostic aid, but as a scalable public health asset.

We invite forward-looking investors to join us in building the first widely deployable, AI-driven triage layer for Alzheimer’s—starting in the Gulf, scaling globally.